List of Excipients in Branded Drug AIRDUO DIGIHALER

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Teva Respiratory LLC	AIRDUO DIGIHALER	fluticasone propionate and salmeterol	59310-111	LACTOSE MONOHYDRATE

AirDuo Digihaler Excipient Strategy and Commercial Opportunities

Last updated: August 7, 2026

AirDuo Digihaler is a breath-actuated dry-powder inhaler containing fluticasone propionate and salmeterol xinafoate. Its excipient platform is deliberately simple: lactose monohydrate is the principal listed inactive ingredient, while the commercial differentiation comes from dose-metering, device engineering and electronic inhalation monitoring rather than a complex formulation [1]. The strongest commercial opportunities are in engineered lactose supply, device-compatible formulation development, authorized-generic strategies, and digital respiratory platforms.

The product faces substantial competition from generic fluticasone propionate/salmeterol inhalers, Advair Diskus, Wixela Inhub and other inhaled corticosteroid/long-acting beta agonist products. Excipient substitution alone is unlikely to create a defensible branded position. The higher-value opportunity is a combined formulation-device platform that improves emitted dose consistency, humidity resistance, adherence monitoring or manufacturing yield.

What is AirDuo Digihaler and how is it formulated?

AirDuo Digihaler is a multidose dry-powder inhaler approved by the FDA for twice-daily treatment of asthma in patients aged 12 years and older who are not adequately controlled on an inhaled corticosteroid or whose disease requires both an inhaled corticosteroid and a long-acting beta agonist [1].

It contains:

Product	Fluticasone propionate	Salmeterol	Device
AirDuo Digihaler 55/14 mcg	55 mcg per actuation	14 mcg per actuation	Electronic multidose DPI
AirDuo Digihaler 113/14 mcg	113 mcg per actuation	14 mcg per actuation	Electronic multidose DPI
AirDuo Digihaler 232/14 mcg	232 mcg per actuation	14 mcg per actuation	Electronic multidose DPI

The labeled inactive ingredient is lactose monohydrate. The lactose contains trace milk proteins, creating a contraindication for patients with severe milk-protein hypersensitivity [1].

The drug substances are micronized and blended with lactose carrier material. The lactose performs several formulation functions:

• It acts as a bulk carrier for low-dose micronized drug particles.
• It improves powder handling and metering.
• It supports dispersion during patient inhalation.
• It enables scalable blending and filling operations.
• It provides a familiar regulatory pathway for dry-powder inhalers.

The formulation therefore depends on the interaction between particle size, carrier morphology, drug loading, blending energy, powder cohesion and inhaler airflow. A change in lactose grade can alter fine-particle fraction, emitted dose, content uniformity and mouth-throat deposition even when the nominal drug concentrations remain unchanged.

What excipients are used in AirDuo Digihaler?

AirDuo Digihaler publicly identifies lactose monohydrate as its inactive ingredient. The FDA labeling does not identify magnesium stearate, leucine, phospholipids, mannitol or a polymeric carrier as formulation excipients [1].

This matters commercially because the product’s excipient strategy is comparatively concentrated. The principal formulation-control variables are likely to include:

1. Lactose particle-size distribution.
2. Carrier surface roughness and fines content.
3. Residual moisture.
4. Bulk density and flowability.
5. Drug-to-carrier ratio.
6. Blend uniformity and segregation behavior.
7. Device resistance and powder deaggregation.

The absence of a broad excipient system reduces raw-material complexity but increases dependence on lactose specifications. A supplier that can maintain tightly controlled morphology, moisture and fines content may have more value than a supplier offering a lower-cost conventional lactose grade.

Why lactose monohydrate is commercially important

Lactose is widely used in inhalation powders, but inhalation-grade lactose is not interchangeable across products. The relevant performance attributes include:

• D10, D50 and D90 particle-size distribution.
• Fine-particle fraction.
• Crystallinity and anomeric composition.
• Surface energy.
• Moisture sorption.
• Bulk and tapped density.
• Flow function coefficient.
• Microbial quality.
• Trace milk-protein content.
• Batch-to-batch morphology.

The commercial opportunity is strongest where a supplier can provide reproducible inhalation-grade lactose with documented extractables, elemental impurities, microbial controls and device-performance data.

How does the excipient strategy affect drug delivery?

AirDuo Digihaler uses a carrier-based dry-powder architecture. Micronized fluticasone propionate and salmeterol particles are difficult to meter and disperse alone because of their low dose and cohesive behavior. Lactose increases powder mass and improves handling, while the patient’s inspiratory flow separates respirable drug particles from the carrier.

The formulation must balance competing objectives:

Objective	Formulation requirement	Commercial consequence
Dose uniformity	Stable drug-carrier blending	Lower batch rejection
High fine-particle fraction	Efficient detachment during inhalation	Better lung delivery
Humidity resistance	Limited moisture uptake	Broader storage robustness
Low powder retention	Appropriate device geometry	Higher delivered dose
Low segregation	Matched density and particle morphology	Better content uniformity
Consistent emitted dose	Controlled powder flow	Reduced device variability

Fluticasone propionate is highly potent and is administered at a low mass per actuation. Salmeterol is also delivered at a relatively low dose. These characteristics make the formulation sensitive to segregation, adhesion to device surfaces and incomplete deaggregation.

A lactose supplier with surface-engineered particles could seek a platform position by demonstrating improved fine-particle delivery without changing the active ingredients or device. Such a change would still require extensive comparative testing because inhaled products are sensitive to the combined formulation-device system.

What formulation patents protect AirDuo Digihaler?

The commercially relevant intellectual property is likely distributed across four categories:

1. Drug formulation and powder-blend architecture.
2. Inhaler dose-metering and airflow design.
3. Electronic sensing and dose-use recording.
4. Manufacturing and assembly processes.

AirDuo Digihaler is a Teva product based on the Digihaler platform. The product’s differentiation is not limited to lactose composition. The electronic module records inhaler-use events and can transmit or display inhalation data through a connected software ecosystem [1, 2].

Public FDA product labeling identifies the formulation and device but does not provide a complete freedom-to-operate analysis for all U.S. patent claims. Patent scope may extend beyond Orange Book-listed patents to device, software, manufacturing and platform patents. For a competing excipient or inhaler developer, the most important barriers may therefore sit outside conventional drug-composition claims.

What formulation changes could create patentable value?

Potentially protectable innovations include:

• A defined lactose morphology that improves emitted dose under high humidity.
• A narrow carrier particle-size distribution combined with a specified drug loading.
• A moisture-control system that preserves fine-particle fraction.
• A co-processed lactose carrier with a defined surface-energy profile.
• A low-retention blister, reservoir or metering interface.
• A powder blend that reduces segregation during shipping.
• A process that increases drug recovery during filling.
• A device-formulation combination that produces consistent delivery across inhalation-flow ranges.

A patent application would need more than a different excipient name. The strongest claims would link composition to measurable performance, such as emitted dose, aerodynamic particle-size distribution, delivered-dose uniformity or stability.

What commercial opportunities exist for AirDuo Digihaler excipients?

1. Inhalation-grade lactose supply

The most direct opportunity is qualification as a second-source or preferred supplier of lactose monohydrate. Value drivers include:

• Tight control of particle morphology.
• Multi-site manufacturing continuity.
• Low and consistent residual moisture.
• Traceability of milk-derived material.
• Regulatory documentation for global markets.
• Reduced variability in emitted dose and fine-particle fraction.

This opportunity is attractive because lactose remains a recurring consumable rather than a one-time device component. The supplier would need to qualify against the existing formulation and demonstrate no adverse effect on dose uniformity or aerosol performance.

2. Excipient platform upgrades

A reformulated product using engineered lactose, mannitol or a force-control agent could target better humidity performance, reduced powder cohesion or improved aerosolization. The development burden would be higher than for a raw-material substitution because the sponsor would need to establish pharmaceutical equivalence or demonstrate an appropriate bridging strategy.

For an inhaled product, laboratory comparisons should include:

• Delivered-dose uniformity.
• Aerodynamic particle-size distribution.
• Fine-particle dose.
• Mass median aerodynamic diameter.
• Geometric standard deviation.
• Spray or plume characterization where relevant.
• Stability under elevated humidity.
• Device retention.
• Flow-rate sensitivity.
• Priming and dose-counter behavior.

3. Authorized generic or platform licensing

AirDuo Digihaler creates a potential licensing platform for companies seeking a connected inhaler rather than a conventional DPI. A partner could license:

• The device architecture.
• Electronic dose-event recording.
• Connectivity software.
• Human-factors data.
• Manufacturing know-how.
• A fluticasone/salmeterol formulation.
• Adaptation to other inhaled combinations.

The commercial value depends on whether the digital module improves adherence, payer value or real-world outcomes enough to justify a premium over generic inhalers. Digital functionality adds hardware, software validation, cybersecurity and support costs. It also creates a larger patent and regulatory perimeter.

4. Combination-product development

The Digihaler platform could support other inhaled corticosteroid/LABA or LAMA/LABA products. The formulation opportunity would be strongest for molecules with:

• Low-dose delivery requirements.
• Poor flowability.
• High sensitivity to humidity.
• A need for dose-use verification.
• Commercial value from adherence monitoring.

A new combination would require separate clinical, device and regulatory development. The existing AirDuo formulation would not automatically provide substitutability for another active ingredient.

How does AirDuo Digihaler compare with competing inhalers?

Product	Active ingredients	Formulation model	Digital monitoring	Competitive position
AirDuo Digihaler	Fluticasone propionate/salmeterol	Lactose-based DPI	Yes	Differentiated by connected device
Advair Diskus	Fluticasone propionate/salmeterol	Carrier-based DPI	No standard integrated monitoring	Originator benchmark
Wixela Inhub	Fluticasone propionate/salmeterol	DPI with integrated dose counter	No equivalent connected ecosystem	Generic-equivalent competitor
Generic fluticasone/salmeterol products	Fluticasone propionate/salmeterol	Product-specific DPI or device	Usually no	Price-driven competition
AirDuo RespiClick	Fluticasone propionate/salmeterol	Carrier-based breath-actuated DPI	No equivalent Digihaler electronics	Earlier Teva platform

AirDuo Digihaler’s commercial advantage is the integrated electronic monitoring capability. Its vulnerability is that many asthma patients and payers evaluate inhalers primarily on clinical equivalence, convenience and cost. A digital feature must produce measurable adherence or outcomes value to offset higher product complexity.

What is the FDA regulatory status and Orange Book position?

AirDuo Digihaler received FDA approval in 2019 through the 505(b)(2) pathway [2]. It is a drug-device combination product with an electronic inhalation-monitoring component. The product is not a biologic, so biosimilar competition is not relevant.

The principal regulatory pathways are:

• A generic application for a therapeutically equivalent fluticasone propionate/salmeterol product.
• A 505(b)(2) application for a reformulated or redesigned product.
• A supplemental application for a modified device or formulation.
• A new drug application for a differentiated connected inhaler.

An ANDA applicant would need to address the reference product’s active ingredients, dosage form, strength, route of administration, device performance and critical quality attributes. A formulation change involving lactose grade may be feasible, but the applicant would need to demonstrate that the change does not materially alter product performance.

Paragraph IV litigation risk depends on the active patent listings and claim scope at the time of filing. Device and software patents may create additional exposure even where composition patents are narrow. A generic company could also face a commercial barrier if the reference product has limited sales and the cost of device replication is high.

The FDA Orange Book should be treated as one part of the patent analysis. It may not capture every patent relevant to a connected inhaler, including patents directed to electronics, data capture, software, assembly or manufacturing [3].

When does AirDuo Digihaler lose exclusivity?

AirDuo Digihaler’s market exclusivity is determined by the interaction of FDA regulatory exclusivity, listed patents and enforceable device or formulation rights. The product was approved in 2019, but approval date alone does not establish the generic-entry date.

Potential exclusivity categories include:

• Five-year new chemical entity exclusivity, if applicable to the regulatory status of the product.
• Three-year exclusivity for qualifying new clinical investigations.
• Patent term and patent-term adjustment.
• Patent-term extension, if granted.
• Pediatric exclusivity.
• Non-Orange Book device or software patents.

The commercial entry date may occur through an at-risk launch, a settlement agreement or a licensed generic arrangement. A definitive launch forecast requires current Orange Book listings, patent litigation records and settlement terms.

What generic entry risks exist for AirDuo Digihaler?

Generic risk is substantial at the active-ingredient level because fluticasone propionate/salmeterol is an established combination. The more difficult question is whether a generic company must replicate the Digihaler’s electronic features or can compete with a nonconnected inhaler.

Key risk factors include:

• Whether the generic references AirDuo Digihaler or another fluticasone/salmeterol product.
• Whether the device is considered integral to the reference product.
• The scope of device and software patent claims.
• FDA requirements for comparative inhaler performance.
• The commercial cost of producing a connected device.
• Payer willingness to reimburse digital functionality.
• Patient preference for a conventional or connected inhaler.

A conventional generic may pressure price without directly replacing every Digihaler feature. A device-matched generic could face greater development costs but may compete more directly for formulary position.

What manufacturing and IP barriers affect commercial entry?

Manufacturing barriers are moderate for the powder itself and higher for the integrated device. Drug blending, micronization, lactose sourcing and capsule or reservoir filling are established technologies. The more difficult controls relate to reproducibility and device integration.

Important barriers include:

• Consistent micronization of both active ingredients.
• Prevention of blend segregation.
• Control of lactose moisture and fines.
• Reliable filling at low drug load.
• Device metering accuracy.
• Electronic sensor calibration.
• Battery life and data integrity.
• Software validation.
• Human-factors performance.
• Combination-product quality systems.

The most defensible commercial position combines formulation know-how with device and software rights. A lactose-only improvement is more likely to support supply or process economics than a durable product monopoly.

What is the revenue exposure and competitive outlook?

Teva does not generally disclose AirDuo Digihaler revenue as a standalone line item in its consolidated public reporting. Product-specific revenue exposure should therefore be assessed through prescription volume, payer coverage, net pricing, royalty arrangements and the performance of Teva’s broader respiratory portfolio rather than through a separately reported figure [4].

The commercial outlook has four scenarios:

Scenario	Formulation impact	Commercial result
Current product maintained	No major excipient change	Focus remains on device differentiation
Engineered lactose substitution	Same active ingredients and device	Potential cost, yield or stability improvement
Reformulated connected DPI	New excipient and device claims	Higher differentiation, higher regulatory burden
Generic or licensed platform	Established actives with alternative device	Price pressure and broader market access

The highest-probability near-term opportunity is supply-chain optimization using qualified inhalation-grade lactose. The highest-value opportunity is a connected DPI platform that demonstrates improved adherence or clinical outcomes. The highest-risk strategy is a broad excipient reformulation without a clear performance advantage.

Key Takeaways

• AirDuo Digihaler uses fluticasone propionate and salmeterol xinafoate in a lactose-monohydrate dry-powder formulation.
• Lactose morphology, moisture, fines and surface properties are central formulation-control variables.
• The product’s primary differentiation is the electronic Digihaler device, not a complex excipient system.
• Engineered lactose can support manufacturing, stability and aerosol-performance improvements.
• A meaningful reformulation would require comparative inhaler-performance data and regulatory bridging.
• Generic competition is likely to focus on the fluticasone/salmeterol combination, while device and software rights may complicate direct Digihaler substitution.
• Biosimilar risk does not apply because AirDuo Digihaler is a small-molecule combination product.
• The strongest commercial opportunities are inhalation-grade lactose supply, authorized-generic development, connected-inhaler licensing and device-formulation combination patents.
• Teva does not separately report AirDuo Digihaler revenue, limiting product-specific revenue analysis from public financial statements.

FAQs

Can lactose monohydrate in AirDuo Digihaler be replaced with mannitol?

Potentially, but the change would create a new formulation requiring comparative aerodynamic, stability, dose-uniformity and device-performance data. Mannitol may alter powder flow, hygroscopicity, taste and drug detachment.

Does AirDuo Digihaler contain magnesium stearate?

The FDA label identifies lactose monohydrate as the inactive ingredient and does not identify magnesium stearate [1].

Is AirDuo Digihaler a biologic eligible for biosimilar competition?

No. It is a small-molecule inhaled corticosteroid/LABA combination. Competition would proceed through generic or 505(b)(2) pathways rather than biosimilar approval.

Can an inhaler company patent a new lactose grade for AirDuo-type products?

Yes, if the grade is tied to a novel composition, manufacturing process or measurable aerosol-performance improvement. A routine particle-size adjustment without unexpected technical effects would provide weaker patent protection.

What is the most attractive licensing opportunity around AirDuo Digihaler?

A connected dry-powder inhaler platform with validated dose-event monitoring, compatible formulation technology and transferable manufacturing know-how has greater licensing potential than a standalone excipient substitution.

References

1. U.S. Food and Drug Administration. (2023). AirDuo Digihaler: Prescribing information. Teva Respiratory, LLC.

2. U.S. Food and Drug Administration. (2019). FDA approves first digital inhaler to help patients with asthma use their medication as prescribed. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. Teva Pharmaceutical Industries Ltd. (2023). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Teva.